These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 31338599)
1. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation. Zhu J; Ke K; Xu L; Jin J J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599 [TBL] [Abstract][Full Text] [Related]
2. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib. Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663 [TBL] [Abstract][Full Text] [Related]
3. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936 [TBL] [Abstract][Full Text] [Related]
4. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations. Zhu J; Wu Y; Xu L; Jin J Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors. Gong YP; Tang LQ; Liu TS; Liu ZP Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363 [TBL] [Abstract][Full Text] [Related]
6. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors. Zhang G; Ren Y Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939 [TBL] [Abstract][Full Text] [Related]
7. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations. Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390 [TBL] [Abstract][Full Text] [Related]
8. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations. Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817 [TBL] [Abstract][Full Text] [Related]
9. Rational Design of Novel Phosphoinositide 3-Kinase Gamma (PI3Kγ) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. Li K; Zhu J; Xu L; Jin J Chem Biodivers; 2019 Jul; 16(7):e1900105. PubMed ID: 31111650 [TBL] [Abstract][Full Text] [Related]
10. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ. Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors. Ma CC; Zhang CM; Tang LQ; Liu ZP Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991 [TBL] [Abstract][Full Text] [Related]
13. Probing the binding mechanism of substituted pyridine derivatives as effective and selective lysine-specific demethylase 1 inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations. Wang ZZ; Yang J; Sun XD; Ma CY; Gao QB; Ding L; Liu HM J Biomol Struct Dyn; 2019 Aug; 37(13):3482-3495. PubMed ID: 30175693 [TBL] [Abstract][Full Text] [Related]
14. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6. Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753 [TBL] [Abstract][Full Text] [Related]
15. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281 [TBL] [Abstract][Full Text] [Related]
16. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies. Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings. Norman P Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077 [TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors. Srivastava S; Singh Choudhary B; Mehta P; Sukanya ; Sharma M; Malik R J Biomol Struct Dyn; 2019 Jun; 37(9):2404-2414. PubMed ID: 30047836 [TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations. Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]